Datavault AI Grants Scilex Exclusive License for Biotech Asset Tokenization Platform

Datavault AI has granted Scilex Holding Company an exclusive worldwide license to deploy its proprietary AI-driven technology within the biotech and biopharma sectors. The agreement enables Scilex to build and operate a Biotech Exchange platform to tokenize, trade, and monetize biotech assets such as genomic data, diagnostics, and drug information. This strategic partnership represents a significant advancement in applying blockchain and artificial intelligence technologies to the life sciences industry.

The licensing arrangement includes substantial financial considerations, with a $10 million upfront payment structured in four installments and up to $2.55 billion in potential milestone payments. This financial structure reflects the significant market potential that both companies see in applying Datavault AI's technology to the biotech sector. The deal is supported by Datavault AI's broad patent portfolio and proven high-performance computing expertise, which provides the technical foundation for the planned exchange platform.

Datavault AI expects the technology to expand beyond the initial Biotech Exchange into a Pharmaceutical Exchange platform addressing an estimated $2 trillion market opportunity. This expansion would provide pharmaceutical companies with innovative pathways to access non-dilutive funding, allowing them to raise capital without giving up equity ownership. The platform's ability to tokenize and monetize various biotech assets could transform how companies value and leverage their intellectual property and data assets in the rapidly evolving digital economy.

The technology deployment builds on Datavault AI's existing platform capabilities, including its Information Data Exchange that enables Digital Twins and licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata objects. This approach fosters responsible AI with integrity while providing comprehensive solutions for experiential data perception, valuation and secure monetization across multiple industries. Additional information about the company's technology offerings can be found at https://www.datavaultsite.com.

For investors seeking current information about Datavault AI's developments, the company maintains an updated newsroom at https://ibn.fm/DVLT. The full details of the licensing agreement and its implications for both companies are available in the complete press release accessible through the company's official communications channels. This partnership represents a significant step in bridging advanced AI and blockchain technologies with the substantial market opportunities in the biotech and pharmaceutical sectors.